GLP1R and type 2 diabetes mellitus: Outcome trials evaluating cardiovascular (CV) effects of glucagon-like peptide-1 (GLP-1) receptor agonists have consistently demonstrated the benefit and safety of these agents in populations with type 2 diabetes (T2D) [1–7].